A Homogeneous Bioluminescent Immunoassay for Parallel Characterization of Binding Between a Panel of Antibodies and a Family of Fcγ Receptors

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jul 16

PMID 35842448

Authors

Nidhi Nath

Becky Godat

Rod Flemming

Marjeta Urh

Affiliations

Soon will be listed here.

Abstract

Fc engineering efforts are increasingly being employed to modulate interaction of antibodies with variety of Fc receptors in an effort to improve the efficacy and safety of the therapeutic antibodies. Among the various Fc receptors, Fc gamma receptors (FcγRs) present on variety of immune cells are especially relevant since they can activate multiple effector functions including antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Depending on the desired mechanism of action (MOA) of the antibody, interactions between Fc domain of the antibody and FcγR (denoted as Fc/FcγR) may need to be enhanced or abolished. Therefore, during the antibody discovery process, biochemical methods are routinely used to measure the affinities of Fc/FcγR interactions. To enable such screening, we developed a plate based, simple to use, homogeneous immunoassays for six FcγRs by leveraging a luminescent protein complementation technology (NanoBiT). An added advantage of the NanoBiT immunoassays is their solution-based format, which minimizes well known surface related artifacts associated with traditional biosensor platforms (e.g., surface plasmon resonance and biolayer interferometry). With NanoBiT FcγRs assays, we demonstrate that assays are specific, report IgG subclass specific affinities and detect modulation in Fc/FcγR interactions in response to the changes in the Fc domain. We subsequently screen a panel of therapeutic antibodies including seven monoclonal antibodies (mAbs) and four polyclonal intravenous immunoglobulin (IVIg) products and highlight the advantages of parallel screening method for developing new antibody therapies.

Citing Articles

Microglial C/EBPβ-Fcgr1 regulatory axis blocking inhibits microglial pyroptosis and improves neurological recovery.

Li J, Yang Y, Zhao C, Zhao J, Wang X, Ye S J Neuroinflammation. 2025; 22(1):29.

PMID: 39891259 PMC: 11786472. DOI: 10.1186/s12974-025-03362-1.

Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders.

Maciuba S, Bowden G, Stratton H, Wisniewski K, Schteingart C, Almagro J MAbs. 2023; 15(1):2254676.

PMID: 37698877 PMC: 10498814. DOI: 10.1080/19420862.2023.2254676.

References

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J . Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015; 112(19):5997-6002. PMC: 4434771. DOI: 10.1073/pnas.1408766112. View

Stephenson K, Le Gars M, Sadoff J, Marit de Groot A, Heerwegh D, Truyers C . Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021; 325(15):1535-1544. PMC: 7953339. DOI: 10.1001/jama.2021.3645. View

Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H . Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018; 10(4):678-691. PMC: 5973752. DOI: 10.1080/19420862.2018.1452580. View

Basgalupp S, Santos G, Bessel M, Garcia L, de Moura A, Rocha A . Diagnostic Properties of Three SARS-CoV-2 Antibody Tests. Diagnostics (Basel). 2021; 11(8). PMC: 8393643. DOI: 10.3390/diagnostics11081441. View

Sebaugh J . Guidelines for accurate EC50/IC50 estimation. Pharm Stat. 2012; 10(2):128-34. DOI: 10.1002/pst.426. View

Janaka S, Clark N, Evans D, Mou H, Farzan M, Connor J . Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay. PLoS One. 2021; 16(7):e0253551. PMC: 8312954. DOI: 10.1371/journal.pone.0253551. View

Francica J, Flynn B, Foulds K, Noe A, Werner A, Moore I . Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med. 2021; 13(607). PMC: 9266840. DOI: 10.1126/scitranslmed.abi4547. View

McRae B, Levin A, Wildenberg M, Koelink P, Bousquet P, Mikaelian I . Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease. J Crohns Colitis. 2015; 10(1):69-76. DOI: 10.1093/ecco-jcc/jjv179. View

10.

Abdiche Y, Yeung Y, Chaparro-Riggers J, Barman I, Strop P, Chin S . The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. 2015; 7(2):331-43. PMC: 4622529. DOI: 10.1080/19420862.2015.1008353. View

11.

Lu J, Chu J, Zou Z, Hamacher N, Rixon M, Sun P . Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci U S A. 2015; 112(3):833-8. PMC: 4311811. DOI: 10.1073/pnas.1418812112. View

12.

Alves J, Engel L, de Vasconcelos Cabral R, Rodrigues E, Ribeiro L, Higa L . A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. Sci Rep. 2021; 11(1):18428. PMC: 8445915. DOI: 10.1038/s41598-021-97330-3. View

13.

Jensen P, Schoch A, Larraillet V, Hilger M, Schlothauer T, Emrich T . A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life. Mol Cell Proteomics. 2017; 16(3):451-456. PMC: 5341005. DOI: 10.1074/mcp.M116.064675. View

14.

Boesch A, Brown E, Cheng H, Ofori M, Normandin E, Nigrovic P . Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014; 6(4):915-27. PMC: 4171026. DOI: 10.4161/mabs.28808. View

15.

Sondermann P, Kaiser J, Jacob U . Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol. 2001; 309(3):737-49. DOI: 10.1006/jmbi.2001.4670. View

16.

Nagelkerke S, Schmidt D, de Haas M, Kuijpers T . Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine. Front Immunol. 2019; 10:2237. PMC: 6786274. DOI: 10.3389/fimmu.2019.02237. View

17.

Selva K, van de Sandt C, Lemke M, Lee C, Shoffner S, Chua B . Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021; 12(1):2037. PMC: 8016934. DOI: 10.1038/s41467-021-22236-7. View

18.

Sazinsky S, Ott R, Silver N, Tidor B, Ravetch J, Wittrup K . Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A. 2008; 105(51):20167-72. PMC: 2629253. DOI: 10.1073/pnas.0809257105. View

19.

Garcia-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P . Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol. 2019; 9:849. PMC: 6763619. DOI: 10.3389/fonc.2019.00849. View

20.

Nimmerjahn F, Ravetch J . Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2007; 8(1):34-47. DOI: 10.1038/nri2206. View